News

The study will focus on the hypertension drug Nilvadipine, which has been found to decrease levels of amyloid in the brain. It is the presence of amyloid in

Vasovist is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. “This approval creates more positive

C326 is an inhibitor of interleukin-6 (IL-6) and is the first in a new class of therapeutic proteins known as Avimer proteins. “We believe that C326 may positively

The Phase II Small Business Innovation Research (SBIR) grant will fund the company’s test based on detection of the HPV-E6 oncoprotein. The E6 protein has been identified as

The findings, presented at the 16th Migraine Trust International Symposium in London, suggest Trexima may address an unmet need among migraine sufferers, who frequently cite inconsistent effectiveness as

Acceptance for filing indicates recognition by the FDA that the submission is complete and warrants full review of the data needed to assess the safety and efficacy of

Methylnaltrexone could be a breakthrough treatment for the bowel condition as there are no medicines currently approved for POI. Methylnaltrexone has received Fast Track designation from the FDA.

Teva Pharmaceutical Industries will fund the costs of the collaboration and pay certain milestones and royalties to Procognia relating to the usage of the technology in the development

AnorMed licensed picoplatin to Poniard Pharmaceuticals (formerly NeoRx Corporation), in April 2004. Under the terms of the new amendment, AnorMed will receive a cash payment of $5 million